White Plains, N.Y.-based White Plains Hospital announces that it has acquired a PET/MRI scanner—which, hospital officials say, offers unparalleled imaging capabilities for cancer detection and assessment of neurological conditions.
A new imaging technique has the potential to detect neurological disorders—such as Alzheimer’s disease—at their earliest stages, enabling physicians to diagnose and treat patients more quickly.
FDG-avid reactive lymphadenopathy on PET/CT has been reported in patients following COVID-19 vaccinations, according to the Society of Nuclear Medicine & Molecular Imaging (SNMMI). Therefore, the SNMMI COVID-19 Task Force has made the following recommendations.
The imaging time window of 64Cu-DOTATATE PET/CT for patients with neuroendocrine neoplasms can be expanded from one hour to three hours post-injection, according to new research published in The Journal of Nuclear Medicine.
Read More
What happens in the brain when our conscious awareness fades during general anesthesia and normal sleep? Finnish scientists studied this question with novel experimental designs and functional brain imaging.
Read MoreAccording to new research, the imaging agent 64Cu-CuSarTate produced high-quality PET images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan.
Read More
PET imaging with 68Ga-pentixafor is an effective diagnostic tool for central nervous system B-cell lymphoma, according to a new study.
Read More
A novel form of an Alzheimer’s protein found in the fluid that surrounds the brain and spinal cord indicates what stage of the disease a person is in, and tracks with tangles of tau protein in the brain, according to a new study using PET imaging.
Read More